Facebook Twitter Instagram
    in evidenza
    • Ius scholae, Baldassarre (Lega): cittadinanza non si regala. I problemi del paese sono altri
    • SALDI_Il bilancio della prima giornata a Genova
    • Vatican News newsletter 02 luglio 2022
    • Variante al piano degli interventi: lunedì 4 luglio una conferenza stampa dell’assessore all’Ambiente Massimiliano De Martin
    • ENERGIA. EUROPA VERDE: GOVERNO CANCELLA TASSA SU EXTRAPROFITTI. LONTANO DAL DRAMMA SOCIALE E AMBIENTALE
    • Comunicato Stampa 02.07 + Articolo Todesco – EGP
    • La Giunta stanzia 2,3 milioni di euro per interventi di messa in sicurezza della viabilità della Terraferma
    • GIOVANI, MATTIA (PD): DA REGIONE LAZIO 13 MLN PER CINQUE BANDI SU FORMAZIONE, CULTURA E ISTRUZIONE
    • Inviaci i tuoi comunicati stampa
    • CONTATTA LA REDAZIONE
    • CONTATTA IL WEBMASTER
    • LA TUA PUBBLICTA’ SU AGENPARL
    Facebook Twitter Instagram
    AgenparlAgenparl
    sabato, Luglio 2
    • Home
    • Italia
      • Politica
        • Interni
      • Cronaca
      • Agroalimentare
      • Arte, cultura, intrattenimento
      • Bandi
      • Difesa
      • Diritto & Giustizia
      • Economia
      • Educazione
      • Lavoro
      • Made In Italy
      • Scienza e Tecnologia
      • Salute
    • Editoriale
    • Internationali
      • Politica estera
      • Agenparl English
      • Agenparl Deutsch
      • Agenparl Española
      • Agenparl French
      • Agenparl Pусский
    • Abbonati
      • ABBONAMENTO DI PROVA
      • NOTIZIARIO
      • RICERCA NEL DATABASE
      • IL MIO ACCOUNT
    • Login
    • AGENPARL
      • LA TUA PUBBLICTà SU AGENPARL
      • Invio Comunicati stampa
      • CONTATTA LA REDAZIONE
      • CONTATTA IL WEBMASTER
    AgenparlAgenparl
    Home»Internazionali»Agenparl English

    FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation

    RedazioneBy Redazione23 Giugno 2022 Agenparl English Nessun commento3 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    (AGENPARL) – SILVER SPRING gio 23 giugno 2022

    On June 22, 2022, the Food and Drug Administration granted accelerated approval to dabrafenib (Tafinlar, Novartis) in combination with trametinib (Mekinist, Novartis) for the treatment of adult and pediatric patients ≥ 6 years of age with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. Dabrafenib in combination with trametinib is not indicated for patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. Dabrafenib is not indicated for patients with wild-type BRAF solid tumors.

    The safety and efficacy were evaluated in 131 adult patients from open-label, multiple cohort trials BRF117019 (NCT) and NCI-MATCH (NCT), 36 pediatric patients from CTMT212X2101 (NCT), and supported by results in COMBI-d, COMBI-v, and BRF113928 (studies in melanoma and lung cancer already described in product labeling). Study BRF117019 enrolled patients with BRAF V600E mutation positive specific solid tumors including high grade glioma (HGG), biliary tract cancer, low grade glioma (LGG), adenocarcinoma of small intestine, gastrointestinal stromal tumor, and anaplastic thyroid cancer (ATC). NCI-MATCH Subprotocol H enrolled adult patients with BRAF V600E mutation positive solid tumors except patients with melanoma, thyroid cancer, or CRC. Parts C and D of Study CTMT212X2101 enrolled 36 pediatric patients with BRAF V600 refractory or recurrent LGG or HGG. The major efficacy outcome measure of these studies was overall response rate (ORR) using standard response criteria. For the 131 adult patients, a total of 54 (41%, 95% CI: 33, 50) experienced an objective response. The studies enrolled patients with 24 tumor types, including different subtypes of LGG and HGG. Among the highest representative tumor types, ORR was 46% (95% CI: 31, 61) for biliary tract cancer, 33% (95% CI: 20, 48) for high grade glioma (combined) and 50% (95% CI: 23, 77) for low grade glioma (combined). For the 36 pediatric patients, the ORR was 25% (95% CI: 12, 42); DOR was ≥6 months for 78% of patients and ≥24 months for 44% of patients.

    The most common (≥20%) adverse reactions in adult patients were pyrexia, fatigue, nausea, rash, chills, headache, hemorrhage, cough, vomiting, constipation, diarrhea, myalgia, arthralgia, and edema.

    The most common (≥20%) adverse reactions in pediatric patients were pyrexia, rash, vomiting, fatigue, dry skin, cough, diarrhea, dermatitis acneiform, headache, abdominal pain, nausea, hemorrhage, constipation, and paronychia.

    The recommended dabrafenib dose in adult patients is 150 mg (two 75 mg capsules) orally twice daily in combination with trametinib 2 mg orally once daily. The recommended doses for dabrafenib and trametinib in pediatric patients are based on body weight. A recommended dose has not been established in patients who weigh less than 26 kg.

    View full prescribing information for Tafinlar and Mekinist

    This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment.

    This application was granted priority review. A description of FDA expedited programs is in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics.

    Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088.

    For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email <a

    For information on the COVID-19 pandemic, see the following resources:

    Follow the Oncology Center of Excellence on Twitter <a href="http://www.twitter.com/@

    Fonte/Source: http://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid

    adult cancer coronavirus Covid19 covidagenparl dabrafenib iorestoacasa patients pediatric
    Redazione

    articoli collegati

    Today in History – July 2

    15% off all books

    Take Steps to Stay Safe From COVID This Weekend 🎆🇺🇸

    CS: “SMAspace” giunge alla sua terza edizione e per la prima volta in modalità phygital: adolescenti e adulti con SMA, famiglie e caregiver insieme ai clinici si incontrano oggi a Roma

    ST 10479 2022 ADD 1

    ST 12955 2020 ADD 1

    Facebook Twitter Instagram Pinterest
    • Inviaci i tuoi comunicati stampa
    • CONTATTA LA REDAZIONE
    • CONTATTA IL WEBMASTER
    • LA TUA PUBBLICTA’ SU AGENPARL
    @tutti i diritti Agenparl 2022

    Type above and press Enter to search. Press Esc to cancel.

    Go to mobile version